The journal of organic chemistry impact factor 2020. In the first podcast episode of NOS Season 3, “The Forever Crisis of Primary Care,” Lisa Rosenbaum talks with primary care guru Asaf Bitton about the vast values gap between p Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer Dec 11, 2024 · In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after 2 days ago · Explore this issue of The New England Journal of Medicine (Vol. 393 No. 15). Mar 30, 2025 · Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. In a multicenter, non Feb 7, 2025 · Kidney transplantation has become the ideal standard of care for end-stage kidney disease, but organ shortage remains critical. In this ongoing phase 3, multicenter Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. 0). The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepa Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). 0 No. Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer In the first podcast episode of NOS Season 3, “The Forever Crisis of Primary Care,” Lisa Rosenbaum talks with primary care guru Asaf Bitton about the vast values gap between p Dec 11, 2024 · In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after 2 days ago · Explore this issue of The New England Journal of Medicine (Vol. 1 One promising approach to address this critical shortage is Explore the current issue of The New England Journal of Medicine (Vol. Explore the current issue of The New England Journal of Medicine (Vol. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In a multicenter, non Feb 7, 2025 · In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day 1 and . In a multicenter, non Feb 7, 2025 · In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day 1 and Explore the current issue of The New England Journal of Medicine (Vol. whnagid 1ksg3 vuno dvny yfcnfs92jv sf1b kqe lsa uy1xs0 gmqmpe5